Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Sepsis 1Infections 1Hematologic Neoplasms 1

Interventions

Voriconazole 4Vancomycin 3Fluconazole 3Filgrastim 3Ciprofloxacin 3Caspofungin 3liposomal amphotericin B 2Trimethoprim, Sulfamethoxazole Drug Combination 2Therapeutics 2Piperacillin, Tazobactam Drug Combination 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Itraconazole 2Granulocyte Colony-Stimulating Factor 2Fosfomycin 2Daptomycin 2Cyclophosphamide 2Cefazolin 2Antibiotic Prophylaxis 2ziprasidone 1threonic acid 1telavancin 1soybean oil, phospholipid emulsion 1plerixafor 1monalizumab 1lime 1human papillomavirus vaccine, L1 type 16, 18 1fluorescein isothiocyanate-keyhole limpet hemocyanin 1fludarabine phosphate 1fish oil triglycerides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Infections × drotrecogin alfa activated × Clear all
NCT00067730 2007-12-07

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

Eli Lilly and Company

Phase 4 Completed
7 enrolled
Other hematologic neoplasm

Infections, Sepsis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡